Abbott Receives FDA’s Emergency Use Authorization for its Point-Of-Care Test to Detect Novel COVID-19 in Five Minutes

Shots:

• Abbott has received the US FDA’s EUA for its molecular point-of-care test to detect novel COVID-19 and runs on its ID NOW platform, delivering positive results in just five mins. and negative results in 13 mins.
• The ID NOW Covid-19 test allows HCPs to perform molecular POC testing outside the hospital in outbreak hotspots. The company anticipates scaling up manufacturing to deliver 50,000 tests/day with its expected launch in next week
•  This marks Abbott’s second FDA’s EUA, following its first EUA for RealTime SARS-CoV-2 test, which runs on m2000 RealTime molecular system for centralized lab environments. Combining both the tests, Abbott expects to produce ~5M tests in April

Click here ­to­ read full press release/ article | Ref: Abbott | Image: Alere